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Purpose
Conditional survival estimates (CSE) can provide additional useful prognostic information
on the period of survival after diagnosis, which helps in counseling patients with cancer on
their individual prognoses. This study aimed to analyze conditional survival (CS) for hepato-
cellular carcinoma (HCC) using a Korean national registry.
Materials and Methods
Patients with HCC, registered in the Korean cancer registry database, were retrospectively
reviewed. Overall survival (OS) was calculated using the Kaplan-Meier method. The 1-year
CS at X year or month after diagnosis were calculated as CS1=OS(X+1)/OS(X). CS calculations
were performed in each Barcelona Clinic Liver Cancer stage, after which patients at stage
0, A, and B underwent subgroup analysis using initial treatment methods. 
Results
A total of 4,063 patients diagnosed with HCC from January 2008 to December 2010, and
2,721 who were diagnosed from January 2011 to December 2012, were separately 
reviewed. In 2008-2010, the 1-year CS of 1, 2, 3, 4, and 5-year survivors was 82.9%, 85.1%,
88.3%, 88.0%, and 88.6%, respectively. Patients demonstrated an increase in CSE over
time in subgroup analysis, especially in the advanced stages. In 2011-2012, the 1-year CS
of 6, 12, 18, 24, 30, and 36 months was 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%,
respectively. The subgroup analysis showed the same tendency towards increased CSE in
the advanced stages.
Conclusion
Overall, the CS improved with each additional year after diagnosis in both groups. CSE may
therefore provide a more accurate prognosis and hopeful message to patients who are sur-
viving with or after treatment.
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Introduction
Hepatocellular carcinoma (HCC) is a common type cancer
and the second most common cause of cancer-related mor-
tality worldwide [1]; it is a significant health issue in Korea
[2]. Although the incidence of HCC has been declining and
the 5-year survival rate has been improving recently in
Korea, in most patients, HCC is still diagnosed in the advan-
ced stage, with extensive tumor burden, vascular invasion,
extrahepatic spread, or decompensated liver function; such
heterogeneous characteristics can affect treatment decisions
and patient survival [3]. In the national randomized registra-
tion report for 2003-2005, the 5-year survival rate of Korean
HCC patients in the modified Union for International Cancer
Control stage I was 52% and 36% in stage II, but only 15% in
stage III, sharply decreasing to 6% in stages IV-A and IV-B
each [2].
Overall survival (OS), measured from the time of diagno-
sis, is a traditional and well-established method to predict
the long-term prognosis of disease [4,5]. However, OS is a
relatively static concept and does not reflect the impact of
changing variables. For instance, preservation of liver func-
tion in patients cured through resection or transarterial ther-
apies is different in each person. The concept of conditional
survival estimates (CSE) applies this heterogeneous and
changeable patient status and determines the probability that
a patient who has survived for a designated period will be
alive at another fixed interval [6-8]. CSE is a simple diagram
that can predict individual risk over a specified period of
time and more accurate prognosis in a group of patients who
are at high risk of death at the beginning of the diagnosis 
[9-12]. Such dynamic prognostic information could help cli-
nicians to provide education, surveillance, management
strategies, and life-changing decisions according to individ-
ual survival characteristics [13].
Till date, the CSE analyses for HCC were limited to spo-
radic single-center reports for patients in early stages of HCC
who had undergone curative treatment [14,15], or those in
advanced stages who had undergone transarterial therapies
[16]. The present study aimed to (1) analyze the large cohort
of HCC patients that was obtained from the Korea cancer
registry database, (2) compare OS and conditional survival
(CS) for HCC patients, and (3) identify CSE according to the
Barcelona Clinic Liver Cancer (BCLC) staging system, which
reflects the patient’s performance status, tumor burden, and
liver function [17].
Materials and Methods
1. Study design
The Ministry of Health and Welfare, South Korea initiated
a nationwide cancer registry in 1980, called the Korea Central
Cancer Registry (KCCR). The C22.0 coding system, which is
based on the International Classification of Disease 10th edi-
tion (ICD-10), was used to abstract HCC patients from the
KCCR registry. The National Cancer Center and Korean
Liver Cancer Study group studied two periods, from January
2008 to December 2010 and from January 2011 to December
2012, in the KCCR database using the random sample audit
method.
A total of 4,597 patients were diagnosed as having HCC
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Cohort A (n=4,063) Cohort B (n=2,721)
1. Performing CSE with subgrouping by BCLC stages
2. Comparing CSE of each BCLC stage 0, A, B with initial treatment
Patients 
excluded (n=398)
Patients 
excluded (n=534)
Korea Cancer Center
Registry (KCCR)
Abstracting patients with HCC
(C22.0 code) using ICD-10 system
+
inspecting two periods
using the random sample audit method
Patients diagnosed as HCC from 
January 2008 to December 2010 
followed up to December 2013 (n=4,597)
Patients diagnosed as HCC from 
January 2011 to December 2012 
followed up to December 2014 (n=3,119)
Exclusion criteria
  < 20 years old
  Survived less than 1 month
  Histologically diagnosed with other disease
  Without listing BCLC stage
  Without listing initial treatment of HCC
Fig. 1. Flow of selection of the study population. HCC, hepatocellular carcinoma; ICD-10, International Classification of
Disease 10th edition; BCLC, Barcelona Clinic Liver Cancer; CSE, conditional survival estimate(s).
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from January 2008 to December 2010 and were followed up
until December 2013 in the Korean cancer registry database.
We excluded 534 patients who (1) were younger than 20
years, (2) survived less than 1 month from the date of diag-
nosis, (3) were finally diagnosed with other diseases such as
neuroendocrine carcinoma, metastatic carcinoma, cholangio-
carcinoma or sarcoma by pathology, (4) did not have the
BCLC stage listed, (5) had no record of the initial treatment
of HCC, or (6) lacked the important clinical or laboratory 
parameters explained below. The remaining 4,063 patients
were referred to as cohort A. For the period from January
2011 to December 2012 and follow-up to December 2014,
3,119 patients were reviewed. Among these, 398 patients
were excluded using the same criteria, and the remaining
2,721 patients were referred to as cohort B. Cohorts A and B
were reviewed separately in this study (Fig. 1).
The primary endpoint was performing CSE with second-
ary subgroup analysis according to the BCLC stages, and sec-
ondary endpoint was comparing CSE of each of the BCLC
stages 0, A, and B, with subgroup analysis according to initial
treatment methods. 
2. Data collection
Clinical parameters included age, sex, presence of chronic
illness such as hypertension or diabetes mellitus, suspected
etiologies of HCC such as viral hepatitis or heavy alcohol 
intake, ascites, hepatic encephalopathy (HEP), number and
maximum size of tumors, presence of portal vein invasion
and metastasis to regional lymph node or distant organ,
Child-Pugh score and classification, model for end-stage
liver disease (MELD) score, BCLC stages at the time of initial
diagnosis, and initial treatment methods. Ascites was re-clas-
sified into “controlled” and “uncontrolled” (grade 2-3) [18],
and HEP was re-classified into “mild” (grade 1-2) and 
“severe” (grade 3-4) according to the West-Haven criteria
[19]. Laboratory parameters included platelet level, serum
sodium, albumin, total bilirubin, creatinine, alanine amino-
transferase, international normalized ratio (INR), and -feto-
protein. The Child-Pugh score was assessed according to the
standard criteria [20]. MELD score were calculated according
to the Malinchoc formula: R=9.57ln(creatinine [mg/dL])+
3.78ln(bilirubin [mg/dL])+11.2ln(INR)+6.43(etiology: 0
if cholestatic or alcoholic, 1 otherwise) [21]. Other clinical or
laboratory parameters were excluded due to insufficient
medical record.
3. Treatment methods
Patients diagnosed with HCC underwent various initial
treatments, including surgical resection, liver transplantation
(LT), local ablation, transarterial therapy, systemic chemo-
therapy (CTx), and radiation therapy (RTx). Local ablation
therapy included radiofrequency ablation (RFA), alcohol 
injection, and other local ablation such as cryoablation. Tran-
sarterial therapy included transarterial chemoembolization
(TACE) with gelatin sponge (gelform), transarterial chemoli-
piodolizaiton (without gelform), TACE with beads, yttrium-
90 radioembolization, and transarterial chemoinfusion via
catheter or intraarterial chemoport. Systemic CTx included
sorafenib and other systemic CTx. Some patients did not 
undergo any treatments.
4. Statistical analysis
Student t test, Mann-Whitney test, chi-square test, or Kappa
statistics were used for comparing variables and calculating
p-values as appropriate. The OS was computed from the day
treatment began until the most recent follow-up or death.
Survival time and rate were estimated using the Kaplan-
Meier method, and differences between groups were assessed
using the log-rank test. Cox proportional hazard ratios were
calculated to test the association between the clinical param-
eters and OS. All variables found to be significant in the uni-
variate analysis were included in the Cox multivariate ana-
lysis. Statistical analyses were conducted using the IBM SPSS
Statistics software, ver. 23.0.0.0 (IBM Corp., Armonk, NY),
and a two-sided p-value of < 0.05 was considered significant.
CS estimates can be calculated from traditional Kaplan-
Meier and actuarial life table survival data. The mathematical
definition of CS is expressed as follows: CS(y|x) is the prob-
ability of surviving for an additional y years or months, given
that the patient has already survived x years or months. If S(t)
is assumed to be the traditional actuarial survival at time t;
CS can be calculated as: CS(y|x)=S(x+y)/S(x). For example,
to determine the 1-year CSE for a patient who has already
survived 2 years, we simply divide the survival estimate at
t=1+2 by the survival at t=2:CS(1|2)=S(5)/S(2).
Cumulative CS calculations were performed with second-
ary subgroup analyses using BCLC stages. Then, additional
subgroup analyses were performed for the patients in stages
0, A, and B using the initial treatment methods.
5. Ethical statement
This study was performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki and was 
approved by the institutional review board of Yonsei Uni-
versity Health System (IRB No. 4-2014-1088). The need for
written informed consent was waived because of the retro-
spective nature.
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Results
1. Patient characteristics
A total of 4,063 patients in cohort A and 2,721 in cohort B
were separately reviewed. The demographics and clinical
characteristics of each group are summarized in Table 1 and
S1 Table.
In Cohort A, during the median follow-up of 33.0 months
(interquartile range [IQR], 7.3 to 50.5), 2,436 patients died,
with a median OS of 10.5 months (IQR, 3.7 to 25.8). The 
median age was 59.0 years (IQR, 51.0 to 68.0), higher with
the mortality (60.0 years; IQR, 52.0 to 69.0; p < 0.001). Male
sex was predominant (77.4%), and chronic hepatitis B was
more frequent than other etiologies (60.7%). Patients with
mortality tended to show further progression in the BCLC
staging system. In cohort B, the median follow-up period
was 27.8 months (IQR, 9.7 to 36.6) shorter than that in cohort
A. The median OS of 1,294 patients with mortality was 8.8
months (IQR, 3.6 to 19.8). Several parameters showed the
same tendency as those seen in cohort A. Although some 
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Table 1.  Baseline characteristics of patients in cohort A (diagnosed in 2008-2010) and cohort B (diagnosed in 2011-2012)
Variables are presented as median (interquartile range) or number (%). LN, lymph node; ALT, aminotransferase; INR, inter-
national normalized ratio; MELD, model for end-stage liver disease; BCLC, Barcelona-clinic liver cancer. a)Student t test,
Mann-Whitney test, chi-square test, or Kappa statistics were used for calculating p-values as appropriate.
Variable Cohort A (n=4,063) Cohort B (n=2,721) p-valuea)
Age (yr) 59.0 (51.0-68.0) 60.0 (52.0-69.0) < 0.001
Male sex 3,144 (77.4) 2,202 (80.9) < 0.001
Body mass index (kg/m2) 23.7 (21.7-25.8) 23.6 (21.6-25.9) 0.824
Hypertension 1,218 (30.0) 887 (32.6) 0.027
Diabetes mellitus 937 (23.1) 632 (23.2) 0.910
Viral etiology 2,962 (72.9) 1,990 (73.1) 0.326
Heavy alcohol intake 1,231 (30.3) 842 (30.9) 0.876
Ascites 889 (21.9) 591 (21.7) 0.968
Hepatic encephalopathy 89 (2.2) 57 (2.1) 0.675
Multiple tumors 1,528 (37.6) 1,009 (37.1) 0.686
Above triple tumors 942 (23.2) 618 (22.7) 0.668
Maximum tumor diameter (cm) 0.858
> 3 2,217 (54.6) 1,468 (54.0) 0.595
Portal vein invasion 905 (22.3) 554 (20.4) 0.060
Regional LN metastasis 263 (6.5) 167 (6.1) 0.578
Distant metastasis 350 (8.6) 236 (8.7) 0.932
Platelet (109/L) 136 (92-197) 141 (96-194) 0.430
Serum sodium (mmol/L) 139 (137-141) 139 (137-141) 0.173
ALT (IU/L) 37.0 (24.0-59.0) 35.0 (23.0-55.0) < 0.001
Albumin (g/L) 3.8 (3.3-4.2) 3.9 (3.3-4.2) < 0.001
Total bilirubin (IU/L) 0.99 (0.70-1.50) 0.90 (0.62-1.40) 0.001
Serum creatinine (IU/L) 0.90 (0.75-1.00) 0.87 (0.72-1.00) 0.101
Prothrombin time (INR) 1.11 (1.04-1.22) 1.10 (1.03-1.19) < 0.001
-Fetoprotein (ng/mL) 41.3 (6.9-625.8) 29.6 (6.3-483.0) 0.680
Child-Pugh class 0.076
B (7-9) 912 (22.4) 569 (20.9) -
C (10-15) 156 (3.8) 88 (3.2) -
MELD 9.00 (7.00-11.00) 8.00 (7.00-10.00) < 0.001
BCLC stage 0.006
Stage A 1,730 (42.6) 1,118 (41.1) -
Stage B 441 (10.9) 319 (11.7) -
Stage C 1,348 (33.2) 870 (32.0) -
Stage D 202 (5.0) 118 (4.3) -
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parameters showed significant differences between two 
cohorts, the mean or median of the parameters was almost
similar.
2. Independent predictor of mortality
In univariate analysis, almost all variables were signifi-
cantly associated with mortality (S2 Table), except the vari-
ables such as hypertension and diabetes mellitus. In the
multivariate analysis (S3 Table), some variables at baseline
were significantly associated with mortality in both cohorts:
age, body mass index, ascites, multiple tumors, maximum
tumor diameter above 3 cm, portal vein invasion, distant
metastasis, serum albumin, prothrombin time, and MELD
score. However, the multivariate analysis contained many
missing values, 987 (24.3%) in cohort A and 476 (12.5%) in
cohort B, respectively.
3. OS and CSE for overall patients
The cumulative survival rates of each BCLC stage, calcu-
lated using Kaplan-Meier analysis, are summarized in Table
2 and Fig. 2. Because of the relatively short follow-up period
of the cohorts, we calculated only 1-year CSE, at 1-year 
intervals in cohort A and 6-month intervals in cohort B.
In cohort A, the OS for overall patients at the time of 1-, 2-,
3-, 4-, 5-, and 6-year survival were 68.3%, 56.6%, 48.2%,
42.5%, 37.4%, and 33.2%, respectively. The 1-year CSE for 1-,
2-, 3-, 4-, and 5-year survivors was 82.9%, 85.1%, 88.3%,
88.0%, and 88.6%, respectively; as is noted, the CSE tended
to increase over time (Table 2, Fig. 3A). In cohort B, the over-
all OS for 1, 2, 3, and 4 years were 72.4%, 60.7%, 51.9%, and
46.1%, respectively. The 1-year CSE for 6, 12, 18, 24, 30, and
36 months were 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%;
this index also showed a tendency increase (Table 2, Fig. 3B).
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4. CSE analyses for each BCLC stage
The OS and 1-year CSE of each BCLC stage were provided
in Table 2 and Fig. 3. Because of a relatively high OS for the
initial 2 years of BCLC stage 0 and A, the initial CSE of the
early stages tended to nearly plateau or even slightly decrea-
sed over time in cohort A. The mortality rates of BCLC stage
C and D were relatively high. The CSE of the advanced
stages tended to increase over time, except a decrease or
blank at the time of 4- and 5-year survival, which was sus-
pected to be caused by the high rate of mortality or failure to
follow-up (Table 2, Fig. 3A). Cohort B also showed nearly
same tendency in CSE as did cohort A, plateauing in the
early stages and increasing over time in the advanced stages
(Table 2, Fig. 3B). The CSE of BCLC stage B was different be-
tween the cohorts, tending to increase in cohort A, but de-
creasing slightly in cohort B.
5. CSE analyses for each subgroup of BCLC stage using ini-
tial treatment methods
The survival analyses of the subgroups using initial treat-
ment methods were performed in each BCLC stage. Fig. 4
and S4 Table demonstrate the OS and CSE of the patients in
cohort A treated with different methods in BCLC stages 0,
A, and B. Increasing tendencies of CSE were shown in pati-
ents who underwent surgical therapy in the early stages and
transarterial therapies in the intermediate stage (Fig. 4). In
Cohort B (Fig. 5, S5 Table), the increasing tendency was not
definitely shown in each subgroup. However, increasing CSE
at the time of the last 3-year survival is seen in patients who
underwent surgery and local ablation in the early stages and
transarterial therapies in the intermediate stage.
6. CSE analyses for each initial treatment modality and
cause of HCC
The OS and 1-year CSE of each initial treatment modality
were provided in S6 Table. Only the patients (n=1,959, 48.2%)
who treated using transarterial methods showed the increas-
ing tendency of 1-year CSE.
For etiologies of HCC, chronic hepatitis B, hepatitis C and
heavy alcohol intake, the CSE analyses were summarized as
S7 Table. For patients with hepatitis B virus, the absolute
value of CSE was higher than patients without hepatitis B
virus; however, the increase in CSE was not significantly dif-
ferent in both cohorts. The result for heavy alcoholics was 
inversely related to the result for chronic hepatitis B. Patients
with heavy alcohol intake showed consistently low 1-year
CSE during the follow-up periods in the two cohorts. About
chronic hepatitis C, there were no any significant findings.
Discussion
In the present study, both cohorts showed a tendency to
increase in the CSE for overall HCC patients, and a greater
increase in the CSE in the advanced stages, in spite of the
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Fig. 4.  One-year conditional survival estimates of each
Barcelona Clinic Liver Cancer (BCLC) subgroup using ini-
tial treatment methods in cohort A, in BCLC 0 (A), BCLC
A (B), and BCLC B (C). "X" yr, 1-year conditional survival
estimates at the time of "X"-year survival.
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high initial mortality. In contrast, CS was minimally changed
or even decreased in the early stages. The excess mortality
seen in the early stage was minimal during the follow-up 
period; therefore, the CSE in the early stages would have
been significantly affected by less mortality. The CSE in 
advanced stages were similar at the same time compared
with those in early stages, even though the OS was shorter.
Thus, when the initial treatment response of patients with
HCC in the advanced stage is good, the prognosis can be 
expected to be similar to that in the early stages. This overall
pattern of the stage-specific CSE was similar to that seen in
population-based studies of several other cancers [22-24]. 
We classified patients with initial treatment method after
classification with the BCLC stage, because the BCLC stage
is determined according to the characteristics of each patients
and tumor heterogeneity at the time of diagnosis and pro-
vides the recommended initial therapy based on the stage
[18]. In general, patients with BCLC stage 0, A, and B undergo
treatment with curative aims, such as surgical resection, LT,
local ablation, localized transarterial therapy, or radiation. In
the subgroup analysis using the initial treatment methods in
each BCLC stage, the CSE tended to increase when the rec-
ommended therapy was performed initially, suggesting the
effectiveness of these treatment methods. However, this
analysis may not be completely accurate, since the long-term
analyses or analyses of the cases of multiple or concurrent
treatment were lacking in this study. The CSE analyses for
each initial treatment modality alone were also done addi-
tionally; however, the results may not be very significant 
because the treatment modality could be affected by the 
patients’ disease status.
In BCLC stage B, the two cohorts showed difference ten-
dencies in CSE. The intermediate and advanced stages 
include a much wider spectrum of disease and patient per-
formance. This increases the range of possible therapies due
to different treatment options, aggressiveness of treatment,
patient tolerance, and varying goals of treatment [25,26].
These can be considered as a limitation of the BCLC staging
system, with difficulty in reflecting the dynamic changes in
the variables; this might have caused the heterogeneity of
CSE analysis seen in this study. Many experts suggested fur-
ther sub-classification of the intermediate stage to overcome
this heterogeneity and provide proper management to indi-
viduals [27-30]. However, the effect of dynamic change of the
individual variables is too difficult to measure and predict
with the initial staging protocols.
Cucchetti et al. [15] investigated CS for cirrhotic patients
in Italy after hepatic resection for HCC. They presented 5-year
CS on various baseline characteristics, but the impact of these
baseline variables influencing the survival is not linear over
time after hepatic resection. The influence of conventional
tumor features such as tumor stage, differentiation degree,
and vascular invasion was seen only for the first 2 years. 
Especially, patients with preserved liver function could 
undergo secondary hepatectomy for recurrent tumor, and
CS for these performed secondary surgery tended to increase.
Facciorusso et al. [14] also analyzed long term CS for HCC 
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Fig. 5.  One-year conditional survival estimates of each
Barcelona Clinic Liver Cancer (BCLC) subgroup using ini-
tial treatment methods in cohort B, in BCLC 0 (A), BCLC
A (B), and BCLC B (C). "X" yr or "X" mo, 1-year conditional
survival estimates at the time of "X"-year or "X"-month sur-
vival.
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patients performed RFA. In this study, the 5-year CS was 
decreased significantly after the third-year follow-up. Because
RFA was often used as an alternative method in patients 
unable to undergo liver resection, the influence of the evolu-
tionary liver function and the clinical parameters of each 
patient would more significantly affect the long-term prog-
nosis. These studies suggested that the dynamic changes in
the clinical course should be considered when predicting the
prognosis of patients with HCC, and the concept of CSE
would provide a useful mechanism to prevent static time-
of-diagnosis risk assessment as a fixed predictive moment.
Another 2-year CS analysis in BCLC B and C using hepatic
arterial infusion chemotherapy (HAIC) with concurrent RTx
(CRT) was carried out in a single tertiary center [16]. In this
study, underlying liver function was seen to have a constant
effect on CS over time. The analysis showed increasing OS
and CS over time in the intermediate and advanced stages;
thus, they concluded that HAIC with CRT could be a hopeful
option for patients, even in advanced stages. Similarly, CS
may enable clinicians to evaluate the consistency of the prog-
nosis to more accurately determine the specific therapy 
required.
Clinicians may, for example, use CS data in an effort to 
institute data-driven optimization of post-therapy surveil-
lance. For instance, many physicians minimize follow-up
surveillance after 3-5 years, often with little justification
based on survival data. Additionally, CS has utility as another
mechanism to detect differentials in population survival pat-
terns. The present study can provide a database based on
large-scale research, meaning that it can be used to predict
the future prognosis based on the information that a partic-
ular patient has at a certain point in time. It is important that
the rise of CSEs ensures that subsequent prognosis can be
better if the survival of patients to a certain point in time is
successful. Additionally, CS may force the physician to 
remember that the risk of death changes as a patient survives
for more time from the diagnosis.
There are several limitations in the present study. First, 
despite enrolling a large number of patients from a national
database, there were insufficient or lacking clinical data for
evaluation of other variables such as performance status 
because of retrospective design; therefore, the application of
other advanced sub-staging systems or additional CSE 
according to the concurrent therapies were not available. Sec-
ond, the follow-up duration was not long enough to confirm
the long-term data regarding CS tendency. A larger cohort
or prospective survival data with sufficient follow-up would
lead to a more accurate CSE, and may provide more helpful
clinical information. Third, this study did not analyze
changes in patient quality of life, socio-economic status, or
disease characteristics and how these affect survival.
In conclusion, the prognosis for overall HCC survivors 
improves with each additional year or month after initial 
diagnosis. Quantitative insight into conditional survival may
be useful for clinicians to help plan optimal cancer surveil-
lance. Patients who are at more advanced stages in particu-
lar, can feel encouraged by their improving prognosis with
every year survived. CS can be a useful tool to predict sur-
vival for HCC patients and provide them with more relevant
and meaningful information concerning the change in their
prognosis over time.
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